Expanding on these findings, our study employs an integrated multi-omics strategy—combining network pharmacology, molecular docking, dynamics simulations, and experimental validation—to investigate how HKC and finerenone synergistically alleviate tubular inflammation and apoptosis in early DN, with a focus on Janus kinase 2 (JAK2/STAT3) pathway inhibition. The gene discussed is JAK2; the disease is liver dysplastic nodule.